

Valby, 18 May 2018

## Lundbeck expands its clinical pipeline

### Potential new treatment for schizophrenia and Alzheimer's disease starts first phase of clinical testing.

H. Lundbeck A/S (Lundbeck) starts the clinical development of a potential new treatment of schizophrenia and Alzheimer's disease. A phase I-study in healthy volunteers with the compound, invented by Lundbeck, has just begun, adding it to Lundbeck's clinical pipeline.

A so-called PDE1-inhibitor, the compound – Lu AF76432 - addresses impaired communication between cells in certain parts of the brain that causes cognitive/functional deficits, e.g. the loss of concentration, loss of memory, the ability to learn and planning of daily tasks. Such cognitive symptoms are prominent in diseases like schizophrenia and Alzheimer's disease, and Lu AF76432 has the potential to help ease these symptoms in patients suffering from these diseases.

"We are delighted to move another Lundbeck invention further forward in development. Cognitive symptoms associated with schizophrenia and Alzheimer's disease have a tremendous negative impact on people's quality of life and ability to function both privately and professionally, so there is a huge need for better treatments of these symptoms", says Anders Gersel Pedersen, Executive Vice President, Research and Development at Lundbeck.

Phosphodiesterase type 1 (PDE1) is an enzyme naturally present in the human brain where it plays an important role in the communication between brain cells. Inhibiting the enzyme increases the presence of a chemical messenger within the cells that improves the communication, in turn improving the cognitive function. The phase I-study is designed to provide information about safety and tolerability, general pharmacokinetic characteristics and to identify maximum tolerated dose.

Further to Lu AF76432, Lundbeck expects to move another 1-2 of its in-house compounds into clinical development during 2018.

### Contacts

Mads Kronborg  
Senior Director, Corporate Communication  
Phone: +45 36 43 40 00  
E-mail: [mavk@lundbeck.com](mailto:mavk@lundbeck.com)



### **About Lundbeck**

H. Lundbeck A/S (LUN.CO, LUN DC, HLUY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind.

Read more at [www.lundbeck.com/global/about-us/progress-in-mind](http://www.lundbeck.com/global/about-us/progress-in-mind).

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. Our research centre is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.2 billion in 2017 (EUR 2.3 billion; USD 2.6 billion).

For additional information, we encourage you to visit our corporate site [www.lundbeck.com](http://www.lundbeck.com) and connect with us on Twitter at @Lundbeck.